* Pacific Biosciences of California Inc reported a quarterly adjusted loss of 22 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -26 cents. The mean expectation of fourteen analysts for the quarter was for a loss of 22 cents per share. Wall Street expected results to range from -30 cents to -16 cents per share.
* Revenue fell 28.2% to $39.97 million from a year ago; analysts expected $41.95 million.
* Pacific Biosciences of California Inc's reported EPS for the quarter was a loss of 22 cents.
* The company reported a quarterly loss of $60.73 million.
* Pacific Biosciences of California Inc shares had risen by 44.1% this quarter and lost 75.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 1.1% in the last three months.
* In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 8 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"
Wall Street's median 12-month price target for Pacific Biosciences of California Inc is $2.75 This summary was machine generated from LSEG data November 8 at 04:28 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.22 -0.22 Met
Jun. 30 2024 -0.23 -0.64 Missed
Mar. 31 2024 -0.28 -0.29 Missed
Dec. 31 2023 -0.29 -0.31 Missed
Comments